We need faster endpoints for targeted cancer drugs, and there is one

As a former regulator, Jorge shares his perspectives for the need of more faster endpoints to measure how targeted cancer drugs can benefit patients. He believes it can be created by combining two commonly used measures. Read more in this short blog.

No Previous Articles

Next Flipbook
Impact of Clinical Trials in Rare Disease and Oncology
Impact of Clinical Trials in Rare Disease and Oncology

×

Let's start a conversation...

First Name
Last Name
Job Title
Company Name
Country
Therapeutic Area Interest - optional
Tell us how we can help
Thank you! We'll be in touch soon.
Error - something went wrong!